The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Size Of The Subcutaneous Immunoglobulin (SCIG) Market Progress Through 2030?
The subcutaneous immunoglobulin (scig) market size has experienced significant growth in recent years. It is forecast to expand from $14.39 billion in 2025 to $16.32 billion in 2026, at a compound annual growth rate (CAGR) of 13.4%. The growth observed historically is a result of factors such as the increasing diagnosis of primary immunodeficiency disorders, the limitations associated with intravenous immunoglobulin therapy, a heightened demand for long-term immune support, the enhanced safety profile of scig, and a rising patient preference for care received at home.
The subcutaneous immunoglobulin (scig) market is anticipated to experience substantial growth in the coming years. It is projected to reach $25.71 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.0%. This expansion during the forecast period is fueled by several factors, such as the broadening of scig applications beyond immunodeficiency, a heightened healthcare focus on homecare options, innovations in infusion device technology, the increasing occurrence of autoimmune and neurological conditions, and a growing desire for patient-focused treatment approaches. Noteworthy trends predicted for this timeframe include a clear shift from IVIG to SCIG therapies, an increased embrace of home-based immunoglobulin administration, a rising preference for devices allowing self-administration, the wider utilization of scig in managing chronic immune disorders, and a greater requirement for ongoing immune replacement therapy.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp
What Key Growth Drivers Are Influencing The Subcutaneous Immunoglobulin (SCIG) Market?
The rising occurrence of secondary immunodeficiency diseases is projected to drive the expansion of the subcutaneous immunoglobulin market in the future. These diseases involve a weakened or compromised immune system originating from factors external to the immune system itself. Key contributors to the prevalence of secondary immunodeficiency diseases include aging populations, the use of immunosuppressive therapies, and exposure to environmental toxins. Subcutaneous immunoglobulin therapy delivers antibodies to reinforce the impaired immune system, particularly in chronic conditions like HIV or autoimmune diseases, helping to prevent infections and maintain immunological function throughout treatment. For example, in October 2024, data from the HIV i-Base, a UK-based treatment activist organization, revealed that in 2023, new HIV diagnoses saw a 36% increase among heterosexual men, climbing from 445 in 2022 to 605, and a 30% increase among heterosexual women, from 602 in 2022 to 780. Consequently, the growing prevalence of secondary immunodeficiency diseases is fueling the growth of the subcutaneous immunoglobulin market.
Subcutaneous Immunoglobulin (SCIG) Market Driver: Rising Neurological Disorders Fuel Growth In The Subcutaneous Immunoglobulin Market
The growing incidence of neurological disorders is anticipated to stimulate the expansion of the subcutaneous immunoglobulin market in the future. A neurological disorder refers to any condition affecting the nervous system, characterized by anatomical, biochemical, or electrical irregularities in the brain, spinal cord, or peripheral nerves, encompassing ailments such as acute spinal cord injury, Alzheimer’s dementia, amyotrophic lateral sclerosis (ALS), ataxia, and brain tumors. The rise in neurological disorders is attributable to several elements, including an aging global population, exposure to environmental toxins, genetic predispositions, and evolving lifestyle patterns. Subcutaneous immunoglobulin therapy offers advantages in managing neurological disorders by supplying antibodies that can regulate immune responses, alleviate inflammation, and stabilize neuromuscular junctions, potentially decelerating disease progression and enhancing symptom management. As an illustration, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that 6.7 million Americans aged 65 and older are currently living with Alzheimer’s dementia, with forecasts suggesting this figure could reach 13.8 million by 2060. Consequently, the increasing prevalence of neurological disorders is a significant factor propelling the growth of the subcutaneous immunoglobulin market.
What Segment Categories Are Evaluated In The Subcutaneous Immunoglobulin (SCIG) Market Study?
The subcutaneous immunoglobulin (scig) market covered in this report is segmented –
1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses
Subsegments:
1) By Immunoglobulin A (IgA): IgA1, IgA2
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4
What Trends Are Affecting The Growth Of The Subcutaneous Immunoglobulin (SCIG) Market?
Leading companies within the subcutaneous immunoglobulin (SCIG) market are concentrating on creating sophisticated solutions, including ready-to-use prefilled formulations, with the goal of increasing treatment convenience, facilitating self-administration, and elevating the overall patient journey. These ready-to-use SCIG formulations are defined as stable, premeasured immunoglobulin products specifically designed for subcutaneous administration, enabling individuals suffering from primary immunodeficiency and other immune conditions to manage their therapy with greater ease beyond traditional clinical environments. An illustrative example occurred in April 2023 when the U.S. Food and Drug Administration (FDA) gave its approval to a 50 mL / 10 g prefilled syringe version of Hizentra (Immune Globulin Subcutaneous [Human] 20%), thereby offering patients a straightforward, prepared-for-use alternative that promotes easier home infusion and boosts compliance with treatment regimens.
Which Companies Are Influencing The Subcutaneous Immunoglobulin (SCIG) Market?
Major companies operating in the subcutaneous immunoglobulin (scig) market are CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, Biotest AG, Bio Products Laboratory Ltd., ADMA Biologics Inc., Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bharat Serums and Vaccines Limited, Emergent BioSolutions Inc., Pfizer Inc., Johnson & Johnson, Lonza Group, Argenx SE, CinnaGen Co., Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd.
Access The Complete Subcutaneous Immunoglobulin (SCIG) Market Report:
Which Region Leads The Subcutaneous Immunoglobulin (SCIG) Market By Size?
North America was the largest region in the subcutaneous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (scig) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Subcutaneous Immunoglobulin (SCIG) Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp
Browse Through More Reports Similar to the Global Subcutaneous Immunoglobulin (SCIG) Market 2026, By The Business Research Company
Subcutaneous Immunoglobulin Scig Market Report 2026
Immunoglobulins Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report
Intravenous Immunoglobulin Market Report 2026
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model